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ABSTRACT 
Over 1 million individuals in the United States experienced a coronary event during 
2019. Following an acute coronary syndrome, patients are initiated on dual antiplatelet 
therapy consisting of aspirin plus a P2Y12 agent to reduce the risk of subsequent 
ischemic events. In this dissertation we use the three-manuscript format to address some 
areas of unmet research related to this therapeutic area. Each manuscript has an abstract, 
introduction, methods, results, discussion, limitations, and conclusion section. 
Manuscript 1: We examined the performance of several different causal modeling 
approaches to real-world data with the objective of addressing selection bias in the 
presence of differential treatment nonadherence in comparative effectiveness research. 
We compared the treatment effect estimates of ticagrelor versus clopidogrel following 
an acute coronary syndrome by applying several analytical approaches, each with 
different levels of adjustment for confounding and treatment nonadherence, to the 
previously published “PLATO” randomized control trial where there was negligible 
differences in protocol adherence among treatment groups. We found that applying a 
time-dependent exposure model adequately adjusted for the imbalance in rate of therapy 
switching and produced an effect estimate congruent to the PLATO trial. 
Manuscript 2: Our objective was to conduct a comparative effectiveness and safety 
analysis of ticagrelor and prasugrel in patients who underwent percutaneous coronary 
intervention after being hospitalized for an acute coronary syndrome. We implemented 
marginal structural models and inverse probability censoring weighting to adjust for 
post-treatment selection bias caused by imbalance in treatment switching and insurance 
disenrollment between comparison groups. We found that implementing a time-
dependent exposure and censor-weighted model, to adjust for the censoring imbalances 
observed in the real-world data cohort, derived results consistent with the recently 
published ISAR-REACT 5 trial. We also found that applying traditional approaches 
derived results that were consistent with previously published observational studies but 
contrary to the RCT.  
Manuscript 3: Our objective was to compare the direct health system costs and 
healthcare resource utilization associated with escalating to either ticagrelor or prasugrel 
following initial clopidogrel treatment due to an acute coronary syndrome. Median per-
member per-month all-cause and cardiovascular-related charges and healthcare 
utilization were evaluated for each patient following escalation. Propensity-score 1:1 
greedy matching was used to adjust for confounders. Generalized linear models were 
used to derive an effect estimate of treatment escalation on outcomes. We found that 
patients who escalate antiplatelet therapy from clopidogrel to ticagrelor experienced 
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This dissertation is written in the manuscript format and is comprised of three 
manuscripts dealing with different aspects of the comparative effectiveness, safety, and 
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Objective: Our objective was to evaluate the comparative effectiveness of clopidogrel 
and ticagrelor in a population similar to the PLATO randomized controlled trial while 
exploring methodologies that best account for imbalanced treatment switching and 
dependent censoring imposed observed in the real-world data. 
Methods: This study used the Optum Clinformatics Datamart and included patients 
aged 18 years or older with an index hospital admission between May 2012 and 
December 2015. Patients with a diagnosis for an acute coronary syndrome treated with 
either clopidogrel or ticagrelor were included. Outcomes included first occurrence of 
death, MI, or stroke to indicate treatment effectiveness. A comparative effectiveness 
evaluation implementing six different study designs to adjusting for post-exposure 
treatment switching and censoring selection bias was conducted to compare to the 
PLATO RCT results. Marginal structural models were employed for multivariate 
confounding, time-dependent exposure, and censoring imbalance adjustments. The five 
analytical approaches were applied to the real-world data cohort included: intention-to-
treat (ITT), as-treated (AT), time-dependent exposure (TD), intention-to-treat with 
censor-weighting (ITT-CW), and time-dependent exposure with censor-weighting (TD-
CW). 
Results: There were 146,310 individuals admitted to the hospital with ACS, of which, 
there were 12,992 (14%) initiated on clopidogrel and 1,557 (1.7%) initiated on 
ticagrelor. The ITT (HR: 0.92; 95%CI: 0.78-1.08) and AT (HR: 0.91; 95%CI: 0.76-
1.10) analysis adjusting for time-fixed confounders derived similar point estimates with 
non-significant findings. The TD method (TD HR: 0.84; 95%CI: 0.71-1.0) adjusting for 
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time-fixed, time-varying exposure and time-varying confounding factors produced a 
point estimate consistent with the PLATO RCT.  
Conclusions: The time-dependent exposure model (TD) produced results from the 
observational data that were close to the PLATO trial. Implementing weights that adjust 
for time-dependent exposure and time-dependent confounding factors can adequately 
account for the switching imbalance.  
 
INTRODUCTION 
Confounding and selection bias are key concerns that must be effectively addressed 
when conducting comparative effectiveness studies that utilize real-world data. Target 
trial emulation is the adaptation of randomized trial concepts to observational studies to 
improve study quality.1 The active comparator, new user (ACNU) design and propensity 
score methods aim to mitigate bias resulting from the inability to randomize treatment 
exposure.2 However, patient adherence to treatment in real-world settings is influenced 
by medication tolerability, adverse events, patient or prescriber preferences, and 
treatment effectiveness. Selection bias will be present if these factors precipitate 
differences in exposure patterns between comparators. For example, censoring patients 
based on differential consequences of treatment can bias results under the assumptions 
of many common analytic approaches.3    
 
A lack of appreciation for selection bias in observational studies may be attributed to 
the following factors. Comparative effectiveness observational studies often employ an 
intention-to-treat (ITT) or a conventional as-treated (AT) analysis.4  While each of these 
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approaches target different causal contrast, a tradeoff between clinical relevance and 
feasibility of obtaining unbiased estimates of the target parameter is made. The ITT 
approach requires the fewest assumptions evaluating the effect of initial treatment 
assignment but may not be the most clinically relevant analysis. Participants are 
followed from the time of treatment initiation (defined by the observational study) until 
preset criteria are reached; irrespective of treatment adherence, switching, or 
discontinuation.5,6 In observational studies, treatment adherence is often omitted.4 
However, adherence should be evaluated and reported in any ITT analysis to add context 
for the interpretation of the effect estimates.4 The traditional Cox model requires the 
assumption that censoring and events are conditionally independent given the 
covariates.7 If the censored events are related to the outcome (conditional on being at 
risk, exposure, and baseline covariates) this assumption does not hold true and may 
invalidate results. In an AT analysis, only the person-time when patients are on 
treatment is evaluated. Patients with nonadherence are censored when deviation from 
initial exposure occurs.5 The effect estimate will be biased if patients discontinue, 
switch, or are lost to follow-up for reasons related to treatment or outcome.8,9 While 
methods for conducting analyses in the presence of informative censoring are not novel, 
censoring is often assumed to be non-differential and not assessed.  
 
In this study, we examined the performance of different analytical approaches for 
addressing selection bias in the presence of differential treatment nonadherence in 
comparative effectiveness research (CER).5 Under the ideal RCT scenario with perfect 
treatment adherence, any approach (ITT, AT, or per-protocol) would yield the same 
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effect estimate. We compared the effect estimates of various observational CER 
strategies, each with different levels of adjustment for confounding and treatment 
nonadherence, to a previously published RCT with negligible differences in protocol 




Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes (PLATO) 
was a double-blind, randomized, trial comparing ticagrelor versus clopidogrel for the 
prevention of cardiovascular events in patients admitted with an acute coronary 
syndrome (ACS). PLATO’s purpose was to determine whether ticagrelor was superior 
to clopidogrel for the prevention of vascular events and death. In the primary ITT 
analysis, after 12-months of follow-up, the risk of the composite endpoint, all-cause 
death, myocardial infarction, or stroke was 16% lower in the ticagrelor group (HR: 0.84; 
95%CI: 0.77-0.92, p<0.001). While there was no significant difference in the rates of 
major bleeding, ticagrelor was associated with a higher rate of major bleeding not 
related to coronary-artery bypass grafting; including more instances of fatal intracranial 
bleeding. Patient adherence to assigned treatment was the same among groups (82.8%) 
with negligible differences in treatment discontinuation (23.4% vs 21.5%). 
 
In order to empirically evaluate the performance of alternative methods for confounder 
adjustment, it was necessary to establish a reference-point or “working gold standard.” 
Therefore, we constructed an empirical cohort to mimic the inclusion/exclusion criteria 
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for the PLATO trial, as closely as possible, using real world data. This performance 
evaluation was imperfect as we recognized that there are multiple reasons why the 
causal effect estimate from real-world data may not be identical to the RCT. However, 




This study utilized the national Optum’s de-identified Clinformatics® Data Mart Database 
(Optum Inc., Eden Prairie, MN) to conduct a retrospective cohort study. This database 
is a large, United States nationwide, managed care, administrative claims dataset 
comprised of longitudinal medical billing information. Insurance claims for all 
pharmacy, inpatient, and outpatient services are included for the enrolled 13 million 
yearly-members. Since this database does not capture over the counter (OTC) 
medication sales, we are not able to assess aspirin use within this population. This 
project achieved the determination of “research not involving human subjects” by the 
University of Rhode Island Institutional Review Board as all data were statistically de-
identified prior to analyses. 
 
Study Cohort 
This study included patients aged 18 years or older with an ACS-related hospital 
admission between May 2012 and September 2015. This period was selected to align 
with the FDA approval of ticagrelor in July 2011 and delayed acceptance into the 
insurance formulary. Patients were required to have a hospital admission with a 
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diagnosis for an ACS treated with either clopidogrel or ticagrelor following discharge. 
ACS diagnosis was identified using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes (ICD-9-CM: 410.x [acute 
myocardial infarction] and 411.x[other acute and subacute forms of ischemic heart 
disease]). Patients were required to have at least 6 months of insurance eligibility prior 
to ACS hospitalization continuing until first pharmacy dispensing of study drug to 
evaluate baseline characteristics and exposure. At least one pharmacy prescription claim 
for either clopidogrel or ticagrelor within 14 days of discharge was required for 
inclusion. Patients with dispensings of P2Y12 antiplatelet agents, history of stroke, 
fibrinolytic therapy within one day of hospitalization, prior dispensings for oral 
anticoagulants, or dispensings of strong Cytochrome P-450 3A inhibitors/inducers 
identified during the baseline period were excluded. Additionally, patients with claims 
for more than one or non-study antiplatelet agent during the 14-day initiation window 
were excluded.  
 
Outcomes Assessment 
The primary outcome was defined as the first occurrence of one of any of the composite 
endpoints: all-cause death, myocardial infarction, or ischemic stroke. All-cause death 
was identified utilizing the Social Security Administration’s Death Master File. Since 
only the month and year of death was included in these data, a day of death was 
randomly assigned within each month for death events occurring after hospital 
discharge. Myocardial infarctions and stroke events were identified by ICD-9-CM 
diagnosis codes (MI: 410-412 [excluding 410.x2]; Stroke: 430-434, 436) occurring 
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during inpatient hospitalization.10,11 Patients were followed from ACS-hospital 
discharge until first endpoint occurrence, loss of insurance eligibility, or for 365 days; 
whichever occurred first. Because patients were initiated on antiplatelet therapy 
immediately and are often sent home with some hospital-dispensed days’ supply, the 
follow-up period begins on the hospital discharge day instead of first outpatient 
prescription dispensing day.  
 
Censoring Assessment 
Censoring events were considered differently for each approach (specified below); but 
included insurance disenrollment, treatment switching, and treatment discontinuation. 
Insurance disenrollment was identified by eligibility end or a gap of 30 days or more in 
insurance enrollment. Treatment switching was identified via pharmacy claims as any 
prescription dispensing for an antiplatelet agent during the follow-up period in place of 
initial treatment. Patients were censored when switched to a non-study agent. Therapy 
discontinuation was defined as greater than 45 days of gap between prescription supply 
end and refill. To remain consistent with clinically appropriate treatment duration, gaps 
greater than 45 days occurring after 6-months of follow-up were not considered as 
discontinuation. Treatment adherence was calculated by a medication possession ratio 
of days’ supply dispensed and days of follow-up. Patients with a medication possession 





Time-fixed covariates, assessed during the 6-month baseline window, included: age, 
sex, hypertension, tobacco use, hyperlipidemia, major bleeding, peripheral vascular 
disease, chronic kidney disease, dialysis, anemia, chronic obstructive pulmonary 
disease, previous percutaneous transluminal angioplasty, previous coronary artery 
bypass graft, congestive heart failure, atrial fibrillation, and beta-blocker, diuretic, 
statin, proton-pump inhibitor, or diabetes medication use.12,13Angina and bleeding 
events requiring hospitalization, including gastrointestinal bleeding and major 
hemorrhage, were included as time-dependent covariates as they are potential indicators 
of inadequate or  excessive platelet inhibition precipitating therapy switching.14–16 
 
Statistical Analysis 
Categorical variables are presented as frequencies (%) and compared using chi-square 
test. Continuous variables are presented as mean ± standard deviation (SD) and 
compared using student t-test. Marginal-structural models (MSM) were fit using inverse 
probability weights (IPW) to adjust for confounding. The robust variance estimator was 
utilized to account for the additional variability introduced by estimating the IPWs. 
Possible violations of positivity and misspecification was assessed in all models by 
inspecting the estimated stabilized weight distribution to check for extreme values and 
to confirm that the mean was approximately equal to one.4 The proportional hazards 
assumption was assessed graphically by examining the IPW log cumulative hazard 
function estimates to ensure that the hazard curves remained parallel over time. 
Standardized differences in covariate means of ≤0.10 were assessed to indicated 





In the time-fixed exposure approaches, the IPWs were derived by a ratio of the marginal 
probability of exposure and the probability of exposure given baseline covariates. The 
weights were used to create a pseudopopulation in which the measured covariates and 
treatment assignment were independent of each other.  
 
Intention-To-Treat (ITT) 
The intention-to-treat analysis in RCTs estimates the average causal effect of assigned 
treatment on the outcome. Whereby, all patients randomized to treatment are included 
in the analysis regardless of adherence to the randomized treatment. This method was 
adapted to our observational data by classifying patients to the treatment they initiated 
following the hospital discharge. Patients were censored if loss of follow-up due to 




An as-treated analysis in RCTs classifies exposure based on the treatment a participant 
actually utilized, instead of following the randomized assignment.14 The as-treated 
analysis estimates the effect of continuous use of the received initial study treatment 
throughout the follow-up. While there are many definitions for an as-treated analogue 
in observational studies, we classified patients to the treatment that was initially 
observed following hospital discharge.17 Patients were censored when insurance 
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disenrollment, treatment discontinuation, or treatment switching occurred following 
initial exposure classification.  
 
Time-Dependent Methods 
Time-Dependent Exposure (TD) 
 The time-dependent weights were constructed to adjust for the previously mentioned 
fixed baseline and time-varying confounding factors.18,19  Exposure was assessed at 
monthly intervals of prescription dispensings for each patient following initial 
assignment and continued until loss of eligibility, switching to non-study treatments, 
treatment discontinuation, event occurrence, or study end. The time-dependent variables 
were assessed during each month of follow-up. Weights for each person-time interval 
were created by the ratio of the probability that each patient received their observed 
treatment conditional on time  and past treatment history divided by the probability that 
the patient received the observed treatment given time, past treatment history, baseline 
covariates, and time-dependent factors.20  
 
Censor Weighting (CW) 
The censor-weighting approach accounted for measured imbalances due to informative 
censoring (e.g., insurance disenrollment, study end). These weights were estimated by 
a ratio of the probability of remaining enrolled in the insurance program for 12-months 
following index hospitalization given time and treatment during time interval divided 
by the conditional probability of remaining enrolled given time, treatment during time 
interval, baseline variables, and time-dependent confounding factors.  The censor 
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weights were applied separately to the observational ITT (ITT-CW) and TD (TD-CW) 
analytic approaches to adjust for the difference in insurance disenrollment between 
treatment groups prior to follow-up end.  
 
RESULTS 
There were 146,310 individuals admitted to the hospital with ACS, of which, 71,287 
(49%) had 6-months of insurance eligibility prior to index hospitalization and 44,338 
(30%) of which were P2Y12-inhibitor new-users. After applying study exclusion 
criteria, there were 12,992 (14%) initiated on clopidogrel and 1,557 (1.7%) initiated on 
ticagrelor (Figure 1). 
 
The clopidogrel group had higher rates of chronic kidney disease, anemia, chronic 
obstructive pulmonary disease, prior coronary artery bypass grafting, congestive heart 
failure, atrial fibrillation, β-blocker use, and diuretic use (Table 1). Patients initiated on 
clopidogrel had a higher rate of loss of insurance eligibility (41% vs. 37%, p=0.09), a 
lower rate of treatment switching (2% vs 18%, p<0.01), lower out of pocket costs 
($9.78/month vs. $56.49/month, p=<0.01), and a longer average of days of follow-up 
(277 ±120 vs. 219 ±136, p<0.01). The rate of outcome events occurring after switching 
among the clopidogrel-to-ticagrelor switchers was much higher than the ticagrelor-to-
clopidogrel switchers (C-T Switchers: 16.7% vs T-C Switchers: 4.6%).  
 
The ITT (HR: 0.92; 95%CI: 0.78-1.08) and AT (HR: 0.91; 95%CI: 0.76-1.10) analysis 
adjusting for time-fixed confounders derived similar point estimates with non-
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significant findings (Table 3). The TD method (TD HR: 0.84; 95%CI: 0.71-1.0) 
adjusting for time-fixed, time-varying exposure and time-varying confounding factors 
produced a point estimate consistent with the PLATO RCT (HR: 0.84; 95% CI: 0.77 – 
0.92). Incorporating censor weights into the traditional ITT approach produced 
consistent results with the conventional methods (ITT-CW HR: 0.92; 95%CI: 0.78-
1.09). Utilizing both the TD and CW weight approaches also derived an estimate 
consistent with the PLATO Trial (TD-CW HR: 0.83; 95%CI: 0.70-0.99). 
 
DISCUSSION 
In our observational study, patients assigned to the ticagrelor group switched treatment 
9 times more frequently than the clopidogrel group (18% vs 2%, p<0.01). Because 
PLATO indicated that ticagrelor was superior to clopidogrel in preventing 
cardiovascular events in this setting, it is plausible that patients who escalated treatment 
from clopidogrel to ticagrelor may have done so for clinical reasons related to worsening 
of ischemic disease. The outcome event rate in the ticagrelor-clopidogrel switchers, 
occurring after switching, remained consistent with the rate observed in patients who 
were assigned to ticagrelor and did not switch (T-C Switchers Event Rate: 4.6% vs T 
Non-switchers: 4.5%). This is an indicator that people switching from ticagrelor to 
clopidogrel may be doing so for reasons unrelated to the outcome, such as cost or 
adverse effects of bleeding.  
 
The outcome event rate in the clopidogrel-ticagrelor switchers, occurring after 
switching, was much higher than the patients who remained on clopidogrel (C-T 
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Switcher Event Rate: 16.7% vs C Non-Switchers: 5.9%). This is likely an indicator that 
escalating treatment from clopidogrel to ticagrelor reflects a higher risk of ischemic 
events. Methods that did not evaluate time-dependent confounding produced effect 
estimates closer to the null suggesting a more protective treatment effect of clopidogrel 
than what was observed in PLATO. Outcomes occurring after treatment switch were 
misclassified to initial exposure in a conventional ITT analysis and not counted when 
censored in the conventional AT analysis. As such, we found a negligible difference in 
the risk of outcome occurrence using ITT and AT analyses (ITT HR: 0.92, p=0.32; AT 
HR: 0.91, p=0.31). 
 
Applying the censor weighting to the intention-to-treat (ITT-CW) analysis resulted in 
an effect estimate that was similar to the initial observational ITT analysis. The 
magnitude of the imbalanced loss to follow-up was not large enough to impact results 
(C: 37% vs T: 41%). We postulate that insurance disenrollment was not related to 
clinical events or measured confounding factors. Thus, the censor weight models could 
not adjust for this slight imbalance with the measured clinical confounders included. 
The time-dependent exposure model (TD) produced results from the observational data 
that were close to the PLATO Trial. Implementing weights that adjust for time-
dependent exposure and time-dependent confounding factors can account for the 
switching imbalance.  
 
Hernán and colleagues have written extensively on implementing the time-dependent 
analysis methods to real-world research. Hernán and Robins propose these methods to 
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improve the traditional per-protocol analyses by adjusting for confounding due to 
incomplete adherence to the assigned treatment. When discussing pragmatic trials, they 
note that adherence and loss to follow-up may be influenced by social and clinical 
factors occurring after randomization. Our data remained consistent with this idea as 
displayed by the switching imbalance observed between exposures. Failing to adjust for 
post-assignment factors can impose confounding and selection bias in some scenarios. 
After we adjusted for time-dependent confounding and treatment, our observational 
results were consistent with PLATO — where this source of bias was minimized.  
 
LIMITATIONS 
First, exact replication of the clinical trial population was not possible with this data 
source. Some of the clinical trial inclusion/exclusion criteria were based on laboratory 
values (e.g., electrocardiography, myocardial necrosis indicators, creatinine clearance, 
and percent of vascular occlusion) and were measured as a part of PLATO enrollment. 
Since the laboratory data is limited within the administrative data, these components of 
the RCT inclusion criteria could not be applied toto our study cohort selection. Second, 
this study could not account for over the counter (OTC) medication utilization, such as 
aspirin. Aspirin is a fundamental aspect of dual-antiplatelet therapy and its utilization 
cannot be measured. Similarly, some non-steroidal anti-inflammatory drugs and proton-
pump inhibitors are also classified as OTC and the potential effects of these agents on 
cardiovascular outcomes or drug-drug interactions could be underestimated. Third, this 
study could not evaluate information regarding type of stent, antiplatelet loading-dose, 
or other particular details of inpatient procedures as such information was not included 
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within the data. Fourth, since 2013 it was no longer mandatory for states to report death 
events to the Social Security Administration.21 As such, deaths occurring after 2013 are 
underreported as the Optum ClinformaticsTM Data Mart utilizes the Social Security 
Administration Death Master File as the source for date of death. Additional limitations 
regarding this data set include generalizability to low income or age 65+ individuals as 
only a portion of these patients are included within this database. Last, there are several 
key assumptions that must be made to obtain correct causal inferences from the time-
varying approaches. We assumed that the measured covariates, including baseline and 
time-varying factors, were sufficient to adjust for both confounding and post-treatment 
selection bias. This assumption is not testable in the observational setting; however, we 
relied on comprehensive literature review and clinical expertise to bolster this 
assumption. We also assumed that the models implemented were correctly specified, 
including the MSM comparing average treatment effects conditional on time-varying 
exposure, baseline covariates, and time-varying confounders. While these assumptions 




Real-world treatment regimens are not static and will change over time in accordance 
with clinical prognosis, patient and provider preferences, treatment tolerance, and non-
clinical factors (cost, insurance coverage, etc.). To answer causal questions on the 
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N = 12,992  
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2. Fibrinolysis within 24hr of 
hospitalization: N = 389  
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6-Month Baseline Period 365-Day Follow-Up 
Possible Censoring Events 
1. Insurance Eligibility End 
2. Treatment Switch 
3. Treatment Discontinuation 
 
14-Day Exposure Window 
ACS Hospital Discharge 
Study Designs: 
1. Intention-to-Treat (ITT) – Exposure: Initial Treatment, Censored: LOE 
2. As-Treated (AT) – Exposure: Initial Treatment, Censored: LOE, Treatment Switch, Treatment Discontinuation 
3. Censoring Weighted Intention-to-Treat (ITT-CW) – Exposure: Initial Treatment, Censored: Weighted by MOE  
4. Time-Dependent (TD) – Exposure: Monthly Treatment, Censor: LOE, Switch to Prasugrel 
5. Time-Dependent Censoring Weighted (TD-CW) – Exposure: Monthly Evaluation, Censored: Weighted by MOE, 
Switch to Prasugrel 





Table 1. Baseline Demographic and Comorbidities by Initial Exposure 
 
  Clopidogrel (%) Ticagrelor (%)  
Characteristics n =  12,992 n =  1,557 P 
Age (±SD) 65.8 ±12 64.2 ±12 0.53 
Female 4,205 (32) 449 (29) <0.01 
Tobacco 3,126 (24) 386 (25) 0.52 
Hypertension 9,931 (76) 1,166 (75) 0.18 
Hyperlipidemia 9,117 (70) 1,119 (72) 0.17 
Carotid Artery Stenosis 4,837 (37) 549 (35) 0.13 
Chronic Kidney Disease 1,248 (10) 110 (7) <0.01 
Anemia 1,463 (11) 143 (9) 0.01 
COPD 2,156 (17) 218 (14) <0.01 
Asthma 726 (6) 74 (5) 0.17 
PTCA 1,005 (8) 128 (8) 0.50 
CABG 699 (5) 62 (4) 0.02 
Congestive Heart Failure 2,513 (19) 268 (17) 0.04 
Atrial Fibrillation 1,175 (9) 106 (7) <0.01 
ACE/ARB 4,810 (37) 556 (36) 0.31 
Beta-Blocker 3,717 (29) 386 (25) <0.01 
Diuretic 2,179 (17) 203 (13) <0.01 
Statin 4,592 (35) 516 (33) 0.09 
Diabetes Med 2,951 (23) 347 (22) 0.70 
Proton-Pump Inhibitor 2,202 (17) 248 (16) 0.31 
Calcium Channel Blocker 445 (3) 46 (3) 0.4 
 
Note: Chronic Obstructive Pulmonary Disease (COPD), Percutaneous Transluminal 
Coronary Angioplasty (PTCA), Coronary Artery Bypass Grafting (CABG), 

















Table 2. Comparing Raw Outcome Frequencies by Initial Exposure 
 
Outcomes Clopidogrel (%) Ticagrelor (%) P  
Value n = 15,953 n = 2,262 
All-cause Death 321 (2) 22 (1) <0.01 
Myocardial Infarction 727 (5) 91 (4) 0.25 
Ischemic Stroke 179 (1) 24 (1) 0.79 






Table 3. Model Results by Analysis Methods 
 
Model Adjusted Hazard Ratio 95% Confidence Interval P-Value 
Unadjusted 0.80 0.58 1.10 0.15 
ITT 0.92 0.78 1.08 0.32 
AT 0.91 0.76 1.10 0.31 
ITT-CW 0.92 0.78 1.09 0.33 
TD 0.84 0.71 1.00 0.06 
TD-CW 0.83 0.70 0.99 0.04 
PLATO Trial 0.84 0.77 0.92 <0.01 
 
Note: Intention-to-treat (ITT), As-treated (AT), Intention-to-treat with censor 
weighting (ITT-CW), Time-dependent exposure (TD), Time-dependent exposure with 










Table 4. Standardized Differences of Baseline Covariates between Two Comparison 
Groups by Analysis Methods  
 
Baseline Characteristics Crude ITT AT ITT-
CW 
TD TD-CW 
Female 0.18 <0.01 0.02 0.05 0.06 0.06 
Tobacco 0.05 <0.01 <0.01 0.03 0.02 0.02 
Hypertension 0.07 <0.01 0.01 0.02 0.03 0.04 
Hyperlipidemia 0.01 <0.01 0.02 0.02 0.02 0.02 
Carotid Artery Stenosis 0.04 <0.01 0.01 <0.01 0.02 0.02 
Peripheral Vascular Disease 0.07 <0.01 <0.01 0.04 0.05 0.05 
Chronic Kidney Disease 0.08 <0.01 0.01 0.01 0.05 0.06 
Dialysis 0.12 0.01 0.02 0.05 0.05 0.09 
Anemia 0.06 <0.01 0.02 0.02 0.03 0.04 
COPD 0.06 <0.01 <0.01 0.03 0.07 0.07 
Asthma 0.12 <0.01 0.01 0.02 0.09 0.09 
PTCA 0.05 0.01 0.02 0.03 0.02 0.03 
CABG 0.01 <0.01 <0.01 0.02 0.01 0.02 
Congestive Heart Failure 0.17 0.01 0.01 0.01 0.09 0.09 
Atrial Fibrillation 0.08 <0.01 0.01 0.03 0.04 0.05 
ACE/ARB 0.08 <0.01 0.01 0.02 0.07 0.08 
Beta-Blocker 0.08 <0.01 0.02 0.02 0.03 0.05 
Diuretic 0.18 0.01 0.01 0.06 0.09 0.12 
Statin 0.11 <0.01 <0.01 0.04 0.06 0.07 
Diabetes Med 0.07 <0.01 0.01 0.01 0.02 0.04 
Proton-Pump Inhibitor 0.02 <0.01 0.01 0.01 <0.01 0.01 
 
Note: Intention-to-treat (ITT), As-treated (AT), Intention-to-treat with censor 
weighting (ITT-CW), Time-dependent exposure (TD), Time-dependent exposure with 
censor weighting (TD-CW), Chronic Obstructive Pulmonary Disease (COPD), 
Percutaneous Transluminal Coronary Angioplasty (PTCA), Coronary Artery Bypass 






Table 5. Distributions of Estimated Stabilized Weights by Analysis Methods 
 
Percentile ITT AT TD ITT-CW TD-CW 
100% Max 1.05 1.05 1.24 1.15 1.27 
99% 1.03 1.03 1.10 1.07 1.09 
95% 1.03 1.03 1.00 1.04 1.04 
90% 1.02 1.02 1.00 1.02 1.02 
75% Q3 1.01 1.01 1.00 1.01 1.00 
50% Median 1.00 1.00 1.00 1.00 0.99 
25% Q1 0.99 0.99 1.00 0.98 0.97 
10% 0.97 0.97 1.00 0.96 0.95 
5% 0.96 0.96 1.00 0.95 0.94 
1% 0.95 0.95 0.94 0.93 0.92 
0% Min 0.92 0.92 0.52 0.89 0.74 
Mean 1.00 1.00 1.00 0.99 0.99 
 
Note: Intention-to-treat (ITT), As-treated (AT), Intention-to-treat with censor 
weighting (ITT-CW), Time-dependent exposure (TD), Time-dependent exposure with 
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Objective: Our objective was to conduct a comparative effectiveness and safety 
analysis of ticagrelor and prasugrel in patients who underwent PCI after being 
hospitalized for an acute coronary syndrome. 
Methods: This study used the Optum Clinformatics Datamart and included patients 
aged 18 years or older with an index hospital admission between May 2012 and 
December 2015, a diagnosis acute coronary syndrome managed with percutaneous 
coronary intervention, and those treated with either ticagrelor or prasugrel. The primary 
outcome was defined as the first occurrence of one of any of the composite endpoints: 
all-cause death, myocardial infarction, or ischemic stroke. The secondary outcome was 
defined as the first occurrence of the composite endpoints: gastrointestinal bleed, 
intracranial hemorrhage, or other major bleeds requiring hospitalization. Weighted Cox 
proportional hazard models and robust variance estimation were implemented to adjust 
for baseline comorbidities, time-varying exposure, time-dependent confounders, and 
differential censoring.  
Results: There were 2,559 (3%) initiated on ticagrelor and 4,456 (5%) initiated on 
prasugrel following PCI. Patients initiated on ticagrelor had a 10% higher rate of 
eligibility disenrollment and a 7% higher rate of medication switching. After adjusting 
for multiple confounding factors, time-varying exposure, and censoring imbalance, 
ticagrelor was associated with a higher risk in all-cause death, MI, and stroke when 
compared to prasugrel (HR: 1.33; 95%CI: 1.04-1.68; p=0.02). Similarly, ticagrelor was 




Conclusion: After adjusting for multiple confounding factors, time-varying exposure, 
and censoring imbalance, prasugrel showed a lower risk in death, MI, and stroke when 
compared to ticagrelor. Similarly, prasugrel was associated with a reduced risk in 
bleeding events.  
 
INTRODUCTION 
Dual antiplatelet therapy (DAPT), consisting of aspirin plus a P2Y12 agent, in patients 
treated with percutaneous coronary intervention (PCI) reduces the risk of subsequent 
ischemic events and has remained a mainstay in treatment for two decades.1–3  The 
Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary 
Treatment (ISAR-REACT) 5 trail was a randomized, open-label study evaluating 
ticagrelor versus prasugrel in patients with acute coronary syndromes (ACS) concluded 
that ticagrelor had significantly higher rates in the incidence of death, myocardial 
infarction, or stroke.4 These findings were unexpected as the authors hypothesized that 
ticagrelor would be superior to prasugrel. Observational studies addressing the head-to-
head comparison of ticagrelor and prasugrel have contradictory results. Dawwas et al. 
evaluated the comparative effectiveness and safety of ticagrelor versus prasugrel in 
patients with ACS.5 Their results indicated that ticagrelor was associated with a 
decreased risk of recurrent nonfatal CVD events and major bleeding events. In contrast, 
some observational studies suggested a benefit with prasugrel over ticagrelor. For 
example, Larmore et al. found that major adverse cardiovascular and major bleeding 
events were lower at 30-days in the prasugrel-treated group when compared to the 




difference between ticagrelor and prasugrel users in adverse cardiovascular and 
bleeding events.7–11 These observational studies did not mention the rate of censoring 
between exposure groups. While patients were censored if treatment switching or 
insurance disenrollment/dropout occur, censoring was assumed to be non-differential 
and negligible between groups even without evaluating these rates.12 Real-world data 
requires a thorough evaluation of the independent censoring assumption to avoid post-
treatment bias and confounding by time dependent confounding factors. 
 
Our objective was to conduct a comparative effectiveness and safety analysis of 
ticagrelor and prasugrel in patients who underwent PCI after being hospitalized for an 
acute coronary syndrome. We implemented marginal structural models and inverse 
probability censoring weighting to adjust for post-treatment selection bias caused by 
imbalance in treatment switching and insurance disenrollment between comparison 
groups. We hypothesized that after adequate adjustment for confounding and selection 
bias, a real-world comparative effectiveness and safety study would obtain results 




We utilized the national Optum’s de-identified Clinformatics® Data Mart Database 
(Optum Inc., Eden Prairie, MN) to conduct a retrospective cohort study. This database 
is a large, United States nationwide, managed care, administrative claims dataset 




pharmacy, inpatient, and outpatient services are included for the enrolled 13 million 
yearly-members.13 This project achieved the determination of “research not involving 
human subjects” by the University of Rhode Island Institutional Review Board as all 
data were statistically de-identified prior to analyses. 
 
Definition of Study Cohort 
Patients aged 18 years or older with a hospital admission between May 2012 and 
December 2015 and a diagnosis of ACS managed with PCI and treated with either 
prasugrel or ticagrelor were included. This period was selected to align with the FDA 
approval of ticagrelor in July 2011 and delayed acceptance into the insurance formulary. 
ACS diagnosis was identified using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes (ICD-9-CM: 410.x [acute 
myocardial infarction] and 411.x[other acute and subacute forms of ischemic heart 
disease]).14 PCI was identified by ICD-9-CM and Current Procedural Terminology 
(CPT-4) procedure codes (ICD‐9‐CM: 00.66, 36.01, 36.02, 36.05, 36.06, 36.07, and 
36.09; CPT‐4: 92980, 92981, 92982, 92984) occurring during the hospitalization 
attributed to the ACS event.11 At least one pharmacy prescription claim for either 
ticagrelor or prasugrel within 14 days of discharge was required for inclusion.11 Patients 
with dispensings of ticagrelor or prasugrel, history of stroke, fibrinolytic therapy within 
one day of hospitalization, prior dispensings for oral anticoagulants, or dispensings of 
strong Cytochrome P-450 3A inhibitors/inducers identified during the baseline period 
were excluded.4,15 Additionally, patients with claims for more than one or any non-study 





The primary outcome was defined as the first occurrence of one of any of the composite 
endpoints: all-cause death, myocardial infarction, or ischemic stroke. All-cause death 
was identified utilizing the Social Security Administration’s Death Master File. Since 
only the month and year of death was included in these data, a day of death was 
randomly assigned within each month for death events occurring after hospital 
discharge. Myocardial infarctions and stroke events were identified by ICD-9-CM 
diagnosis codes (MI: 410-412 [excluding 410.x2]; Stroke: 430-434, 436) occurring 
during inpatient hospitalization.16,17 The secondary outcome was defined as the first 
occurrence of the composite endpoints: gastrointestinal bleed, intracranial hemorrhage, 
or other major bleeds requiring hospitalization.18 Patients were followed from PCI-
hospital discharge until first endpoint occurrence, loss of insurance eligibility, or for 
365 days; whichever occurred first.  
 
Censoring Assessment 
Censoring events included insurance disenrollment, treatment switching, and treatment 
discontinuation. Insurance disenrollment was identified by eligibility end or a gap of 30 
days or more in insurance enrollment. Treatment switching was classified by the 
discontinuation of the initially assigned agent and subsequent replacement of an 
alternative agent, as identified via prescription pharmacy claims. Patients were censored 
when switched to a non-study agent (i.e. clopidogrel). Therapy discontinuation was 
defined as a greater than 45 days of gap between prescription supply end and refill. 








Baseline covariates, assessed during the 6-month baseline window, included: age, sex, 
hypertension, tobacco use, hyperlipidemia, major bleeding, peripheral vascular disease, 
chronic kidney disease, dialysis, anemia, chronic obstructive pulmonary disease, 
previous percutaneous transluminal angioplasty, previous coronary artery bypass graft, 
congestive heart failure, atrial fibrillation, and beta-blocker, diuretic, statin, proton-
pump inhibitor, or diabetes medication use.19,20 Angina, prior interval treatment, and 




Categorical variables are presented as frequencies (%) and compared using chi-square 
test. Continuous variables are presented as mean ± standard deviation (SD) and 
compared using student t-test. Marginal-structural models (MSM) were fit using inverse 
probability weights (IPW) to adjust for confounding with time-dependent variables.21,22 
Possible violations of positivity and misspecification was assessed in all models by 
inspecting the estimated stabilized weight distribution to check for extreme values and 
to confirm that the mean was approximately equal to one.23 The proportional hazards 
assumption was assessed graphically by examining the IPW log cumulative hazard 




Time-Dependent Exposure (TD) 
Weighted Cox proportional hazard models and robust variance estimation were 
implemented to adjust for baseline and time-dependent confounders.24,25  The robust 
variance estimator was required to account for the additional variability introduced by 
estimating the IPWs. The time-dependent weights were constructed to adjust for fixed 
baseline and time-varying confounding factors.  Exposure was assessed at monthly 
intervals of prescription dispensings for each patient following initial assignment and 
continued until loss of eligibility, switching to non-study treatments, treatment 
discontinuation, event occurrence, or study end. Weights for each person-time interval 
were created by the ratio of the probability that each patient received their observed 
treatment conditional on time,  and past treatment divided by the probability that the 
patient received the observed treatment given time, past treatment, baseline covariates, 
and prognostic (time-dependent) factors.26  
 
Censoring Weighting (CW) 
The censor-weighting accounted for possible informative censoring (e.g., insurance 
disenrollment) due to measured confounding factors. These weights were estimated by 
a ratio of the probability of remaining enrolled in the insurance program for 12-months 
following index hospitalization given time, prior treatment divided by the conditional 
probability of remaining enrolled given time, prior treatment, baseline variables, and 
time-dependent confounding factors.26,27 The time-dependent exposure and censoring 






Intention-To-Treat Analysis (ITT) 
A conventional ITT analysis was conducted to remain consistent with the approaches 
used in previously published observational studies. Patients were censored if loss of 
follow-up due to insurance disenrollment but were not censored based on treatment 
discontinuation, adherence, or switching. The IPWs were derived by a ratio of the 
marginal probability of exposure and the probability of exposure given baseline 
covariates.28 The weights were used to create a pseudopopulation in which the measured 
covariates and treatment assignment were independent of each other. No adjustments 
were made for time-dependent confounding factors. We hypothesized that not adjusting 
for dropout or switching imbalances between exposure groups would bias results toward 
the null. 
 
Clopidogrel Naïve Population 
To determine if the clopidogrel exposure during baseline period impacts conclusions, 
we narrowed the population to antiplatelet-naïve patients by excluding those with 
clopidogrel exposure during the baseline period. While the ISAR-REACT 5 trial 
allowed patients with a history of clopidogrel use to enroll, we hypothesized that the 








There were 91,682 individuals admitted to the hospital with an acute coronary syndrome 
who underwent percutaneous coronary intervention during a hospitalization for an acute 
coronary syndrome. Only 71,287 (78%) had 6-months of insurance eligibility prior to 
index hospitalization. After applying the exclusion criteria, there were 2,559 (3%) 
initiated on ticagrelor and 4,456 (5%) initiated on prasugrel following PCI (Figure 1). 
 
The ticagrelor group had significantly higher rates of comorbidities at baseline (Table 
1). The ticagrelor group was older, had higher rates of hypertension, chronic kidney 
disease, anemia, chronic obstructive pulmonary disease, congestive heart failure, and 
atrial fibrillation. Patients initiated on ticagrelor had a 10% higher rate of eligibility 
disenrollment and a 7% higher rate of medication switching (Table 2). The ticagrelor 
group had a 2% higher frequency of prior clopidogrel users compared to the prasugrel 
group. Treatment discontinuation was balanced between groups.  
 
Comparative Effectiveness Results 
The composite outcome death, myocardial infarction, and ischemic stroke occurred 
more frequently in the ticagrelor group (Table 3). Gastrointestinal bleeding, intracranial 
hemorrhage, and other major bleeding requiring hospitalization were also more frequent 
in the ticagrelor group, although neither were statistically significant. After adjusting 
for multiple confounding factors, time-varying exposure, and censoring imbalance, 
ticagrelor was associated with a higher risk in all-cause death, MI, and stroke when 




ticagrelor was associated with a higher risk in bleeding events (HR: 1.61; 95%CI: 1.19-
2.17; p<0.01).  
 
Sensitivity Analysis Results 
Intention-To-Treat Analysis (ITT) 
The conventional ITT analysis that did not adjust for the disenrollment or switching 
imbalance between groups derived estimates in the opposite direction. The ITT 
approach associated ticagrelor with a lower rate of all-cause death, MI, and stroke (HR: 
0.78; 95%CI: 0.58-1.06; p=0.11) and lower risk in bleeding events (HR: 0.84; 95%CI: 
0.58-1.20, p=0.33), although these results were non-significant.  
 
Clopidogrel Naïve Population 
Results were similar to the original study population (where prior clopidogrel use was 
allowed). The TD-CW method for primary (HR: 1.28; 95%CI: 0.99-1.66; p=0.06) and 
secondary (HR: 1.63; 95%CI: 1.19-2.23, p<0.01) composite outcomes remained 
consistent. Similarly, ITT results for the primary (HR: 0.81; 95%CI: 0.59-1.11; p=0.19) 
and secondary (HR: 1.05; 95%CI: 0.73-1.51; p=0.79) were consistent with the original 
population with less precision.  
 
DISCUSSION 
This study was consistent with the ISAR-REACT 5 trial that showed that prasugrel was 
associated with a lower risk of ischemic and bleeding events in patients treated for ACS. 




affinity following PCI, many factors can influence treatment selection potentially 
explaining the observed imbalances between disenrollment or antiplatelet switching.19,29 
While most observational studies adjust for baseline imbalances between groups, post-
exposure events are not often evaluated. We implemented a time-dependent exposure 
and censor weighted model to adjust for the censoring imbalances identified in Table 2. 
Utilizing this approach produced results consistent with the ISAR-REACT 5 trial with 
a cohort where dropout and treatment switching rates between randomized groups were 
negligible.  
 
The observational literature about outcomes of antiplatelet use have competing 
results.5,7–11,20 Variability in follow-up time, study approaches, and assumptions 
contribute to a breadth of conclusions. It is not appropriate to implement a conventional 
ITT analytic approach when censoring events are imbalanced between treatment groups 
and differential censoring is present. Our ITT sensitivity analysis provided results that 
were consistent with recent observational studies evaluating these agents and contrary 
to the ISAR-REACT 5 trial. It was evident that ignoring differential post-assignment 
imbalances between exposure groups can produce results in the opposite direction and 
may contribute to the variability of results in observational studies. 
 
While there was a statistically significant 2% higher rate in clopidogrel exposure 
identified during the baseline period of the ticagrelor group, narrowing the population 
to antiplatelet-naïve patients by excluding those with prior clopidogrel exposure 








First, the balance between ischemic and bleeding risk plays an integral role in treatment 
selection. As this evaluation is conducted by the clinician on a patient-by-patient basis, 
misclassification, under reporting, or events occurring greater than 6-months in the past 
were not incorporated into the treatment weights. Second, this study could not account 
for over-the-counter (OTC) medication utilization, such as aspirin. Aspirin is a 
fundamental aspect of dual-antiplatelet therapy and its utilization cannot be measured. 
Similarly, some non-steroidal anti-inflammatory drugs and proton-pump inhibitors are 
also classified as OTC and the potential effects of these agents on cardiovascular 
outcomes or drug-drug interactions could be underestimated. Third, this study could not 
evaluate information regarding type of stent, antiplatelet loading-dose, or other details 
of inpatient procedures as such information was not included within the data. Fourth, 
since 2013 it was no longer mandatory for states to report death events to the Social 
Security Administration.30 As such, deaths occurring after 2013 are underreported as 
the Optum ClinformaticsTM Data Mart utilizes the Social Security Administration Death 
Master File as the source for date of death. Additional limitations regarding this data set 
include generalizability to low income or age 65+ individuals as only a portion of these 
patients are included within this database. Last, there are several key assumptions that 
must be made to obtain correct causal inferences from the time-varying approaches. We 




sufficient to adjust for both confounding and post-treatment selection bias.. This 
assumption is not testable in the observational setting; however, we relied on 
comprehensive literature review and clinical expertise to bolster this assumption. We 
also assumed that the models implemented were correctly specified, including the MSM 
comparing average treatment effects conditional on time-varying exposure, baseline 
covariates, and time-varying confounders. While these assumptions are not testable, we 
fit the same covariates in all models to make these results comparable.  
 
CONCLUSION 
Marginal structural models with IPTW and IPCW were utilized to adjust for imbalances 
in post-exposure variables, in addition to baseline confounders, that would have 
imposed a differential and dependent censoring. After adjusting for multiple 
confounding factors, time-varying exposure, and censoring imbalance, prasugrel 
showed a lower risk in death, MI, and stroke when compared to ticagrelor. Similarly, 
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N = 2,559 
Prasugrel 
N = 4,456 
Exclusions: 
1. PCI-ACS Discharge Prior to 
01March2012: N = 14,150 
2. Fibrinolysis within 24hr of 
hospitalization: N = 347 
3. Anticoagulant use at baseline:  
N = 2,309 
4. CYP-450 3A inducer or inhibitor 
(strong): N = 4,451 
5. History of intracranial 
hemorrhage: N = 89 
N = 21,346 
Clopidogrel 




N = 91,682 
6-Month baseline 
insurance eligibility 
N = 71,287 
Antiplatelet 
initiators 
N = 44,238 
No antiplatelet dispensing 
within 14-days of discharge 
N = 27,049 
Study Population 




Table 1. Baseline Characteristics by Initial Exposure 
 
  Ticagrelor (%) Prasugrel (%) 
 
Characteristics n =  2,559 n =  4,456 P 
Age (±SD) 65.3 ±11.7 59.8 ±10.2 <0.01 
Female 820 (31) 968 (21) <0.01 
Tobacco Use 633 (24) 1,195 (26) 0.04 
Hypertension 2,041 (77) 3,233 (71) <0.01 
Hyperlipidemia 1,916 (73) 3,338 (73) 0.64 
Carotid Artery Stenosis 126 (5) 143 (3) <0.01 
Chronic Kidney Disease 231 (9) 282 (6) <0.01 
Anemia 277 (10) 308 (7) <0.01 
Chronic Obstructive 
Pulmonary Disease 
386 (15) 503 (11) <0.01 
Asthma 133 (5) 204 (4) 0.27 
Percutaneous Transluminal 
Coronary Angioplasty 
271 (10) 410 (9) 0.07 
Coronary Artery Bypass 
Graft 
136 (5) 199 (4) 0.12 
Congestive Heart Failure 514 (19) 727 (16) <0.01 




1,027 (39) 1,605 (35) <0.01 
Beta-Blocker 778 (29) 1,105 (24) <0.01 
Diuretic 425 (16) 561 (12) <0.01 
Statin 999 (38) 1,581 (35) <0.01 
Diabetic Medication 654 (25) 1,058 (23) 0.12 
Proton-Pump Inhibitor 464 (18) 646 (14) <0.01 





Table 2. Censoring Frequencies by Initial Exposure 
 
  Ticagrelor (%) Prasugrel (%) P 
Value 
Censoring Criterion n = 2,639 n = 4,566 
Insurance Disenrollment 
During Follow-up 
1493 (57) 2139 (47) <0.01 
Medication Switch 931 (35) 1278 (28) <0.01 
Switch to Clopidogrel 815 (88) 1273 (100) 
 















n = 4,566 
P 
value 
All-cause Death 33 (1.3) 60 (1.3) 0.82 
Myocardial Infarction 109 (4.1) 150 (3.3) 0.06 
Stroke 29 (1.1) 24 (0.5) <0.01 






Gastrointestinal Bleed 63 (2.4) 84 (1.8) 0.11 
Other Major Bleed 29 (1.1) 41 (0.9) 0.40 
Intracranial 
Hemorrhage 
11 (0.4) 17 (0.4) 0.77 






Table 4. Adjusted Hazard Ratios for Ischemic and Bleeding Events by Analysis 
Methods 
 
Time-Dependent Censor-Weighted (TD-CW) HR 95% Cl P 
All-cause death, MI, Stroke 1.33 1.04 1.69 0.02 
ICH, GI Bleed, Major Hemorrhage 1.61 1.19 2.17 <0.01 
Intention-to-Treat (ITT)   
  
  
All-cause death, MI, Stroke 0.78 0.58 1.06 0.11 
ICH, GI Bleed, Major Hemorrhage 0.84 0.58 1.20 0.33 
Clopidogrel-Naive TD-CW   
   
All-cause death, MI, Stroke 1.28 0.99 1.66 0.06 
ICH, GI Bleed, Major Hemorrhage 1.63 1.19 2.23 <0.01 
Clopidogrel-Naive ITT       
 
All-cause death, MI, Stroke 0.81 0.59 1.11 0.19 
ICH, GI Bleed, Major Hemorrhage 1.05 0.73 1.51 0.79 
Note: Myocardial infarction (MI), intracranial hemorrhage (ICH), gastrointestinal 













































Figure 3. Estimated survival curve for gastrointestinal (GI) bleed, intracranial 
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Background: For patients with an acute coronary syndrome (ACS) treated with 
clopidogrel, switching to ticagrelor or prasugrel represents a clinical treatment 
escalation. There is a lack of research evaluating the costs and frequency of healthcare 
encounters associated with this treatment escalation.   
Objectives: To compare the direct drug and health system costs and healthcare resource 
utilization (HRU) associated with escalating from clopidogrel, to either ticagrelor or 
prasugrel following an ACS. 
Methods: This retrospective cohort study used the Optum ClinformaticsTM database 
to study patients that escalated antiplatelet therapy following an ACS from 2012 to 
2015. Patients were followed for up to 12-months following date of switch from 
clopidogrel, until insurance disenrollment, or death. Median per-patient per-month 
(PPPM) all-cause and cardiovascular-related (CV) charges and healthcare utilization 
were evaluated for each patient following escalation. CV medical encounter cost 
included subsequent ACS, revascularization, or stroke events. CV prescription costs 
included charges attributed to beta-blockers, ACE/ARBS, diuretics, antiarrhythmics, 
statins, fibric acid derivatives, bile acid sequestrants, calcium channel blockers, and 
anticoagulants. Propensity-score (PS) 1:1 greedy matching was used to adjust for 
confounders. All cause and CV charges, and frequencies of HRU were compared 
between the two PS-matched groups of ticagrelor and prasugrel escalators. To assess 
the effect of treatment escalation on costs and healthcare resource utilization generalized 
linear models were fitted using a log-link function with gamma distribution or 




Results: There were 21,103 (23%) patients initiated on clopidogrel, 5,040 (6%) initiated 
on prasugrel, and 2,974 (3%) initiated on ticagrelor lowing PCI. Of the clopidogrel 
initiators, 132 switched to ticagrelor and 281 switched to prasugrel within 1 year of 
initial therapy. Patients who escalated to ticagrelor experienced 33% lower all-cause 
costs (RR: 0.67, 95%CI: 0.44-0.99, p=0.05) when compared to those switching to 
prasugrel. There was no significant difference found in all-cause outpatient (RR: 0.94, 
95%CI: 0.60-1.48, p=0.80), hospitalizations (RR: 0.58, 95%CI: 0.31-1.07, p=0.08), or 
prescription (RR: 0.82, 95%CI: 0.64-1.05, p=0.12) costs. : 0.58, 95%CI: 0.31-1.07, 
p=0.08), or prescription (RR: 0.82, 95%CI: 0.64-1.05, p=0.12) costs. The ticagrelor 
escalators also experienced 49% lower CV-related total costs (RR: 0.51, 95%CI: 0.33-
0.76, p<0.01) driven by the 61% lower CV inpatient costs (RR: 0.39, 95%CI: 0.16-0.96, 
p=0.04). 
Conclusion: We found that patients escalating antiplatelet therapy from clopidogrel to 
ticagrelor were associated with less total all-cause costs and total cardiovascular-related 
costs driven by lower cardiovascular-related hospitalization costs when compared to 












Dual antiplatelet therapy, consisting of an oral P2Y12-inhibitor and aspirin, is the 
standard of care for the preventing ischemic events in patients with acute coronary 
syndrome (ACS).1,2 Pharmacodynamic and randomized controlled trials show that 
ticagrelor and prasugrel are associated with enhanced antiplatelet effects and reduced 
ischemic outcomes when compared to clopidogrel.3,4 Even though clopidogrel and 
prasugrel are both thienopyridines, prodrugs that rely on first pass metabolism for 
conversion into their active forms and bind to the same location on the P2Y12 receptor, 
prasugrel activation is less dependent on hepatic metabolism resulting in a more potent 
and consistent inhibition of platelets.5 Ticagrelor, a triazolopyrimidine, does not require 
first-pass activation, binds to a different site on the P2Y12-receptor, and is readily 
absorbed. Switching between different oral P2Y12-inhibitors after being treated on an 
initial agent can occur in an effort to leverage these differences in pharmacodynamic 
activity to improve subsequent clinical outcomes. 
   
Switching to ticagrelor or prasugrel can indicate an escalation in therapy and is an option 
in patients who have an ACS event while already being treated with clopidogrel.6 
However, there is limited  research regarding the clinical and economic outcomes 
related to this type of switch as patients with prior P2Y12-inhibitor treatment are often 
excluded from analyses.7 Registry studies indicate that the prevalence of escalating from 
clopidogrel is between 5-50% depending on the clinical setting, but were not designed 
to assess clinical outcomes.8–10 All pharmacodynamic studies have shown increased 




however there have been no studies evaluating costs and healthcare resource utilization 
(HRU) associated with this therapy change.11–14 There have been several studies 
comparing costs between patients who are treated with antiplatelet agents following 
ACS, but none evaluating those that escalate therapy.15–18 The most recent compared 6-
month costs between all oral antiplatelet agents following acute coronary syndromes 
and did not find significant differences between ticagrelor and prasugrel in costs but 
higher HRU in ticagrelor patients. Our objective was to compare the direct health system 
costs and healthcare resource utilization associated with escalating to either ticagrelor 
or prasugrel following initial clopidogrel treatment due to an ACS event. We aimed to 
determine if the pharmacodynamic differences between ticagrelor and prasugrel 
translate to differences in costs or HRU and if escalating to one agent is more 




This study utilized the national Optum’s de-identified Clinformatics® Data Mart 
Database (Optum Inc., Eden Prairie, MN) to conduct a retrospective cohort study. This 
database is a large, United States nationwide, managed care, administrative claims 
dataset comprised of longitudinal medical billing information. Insurance claims for all 
pharmacy, inpatient, and outpatient services are included for the enrolled 13 million 
yearly-members.19 Mortality was identified from the Social Security Death Index 




subjects” by the University of Rhode Island Institutional Review Board as all data were 
statistically de-identified prior to analyses. 
 
Definition of Study Cohort 
The study included patients aged 18 years or older with a hospital admission between 
January 2012 and September 2015 and a diagnosis of ACS treated with clopidogrel. 
ACS diagnosis was identified using the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) codes (ICD-9-CM: 410.x [acute 
myocardial infarction] and 411.x[other acute and subacute forms of ischemic heart 
disease]).20 Patients with their first outpatient prescription dispensing of an antiplatelet 
agent within 14 days of discharge for clopidogrel were included. Patients that 
permanently switched to either ticagrelor or prasugrel at any point, defined by pharmacy 
claims where clopidogrel dispensings were discontinued and replaced with the study 
treatments, were included. Patients that remained on clopidogrel for the duration of 
treatment were not evaluated in this study. At least one year of continuous insurance 
eligibility, with at least 6-months of eligibility prior to index ACS hospitalization, were 
required for inclusion. Patients were followed for up to 12-months following date of 
switch from clopidogrel, until insurance disenrollment, or death.    
 
Baseline Confounders 
Comorbidities were assessed using diagnosis codes queried within inpatient and 
outpatient medical claims during the 6-months baseline period occurring prior to the 




hyperlipidemia, major bleeding, peripheral vascular disease, chronic kidney disease, 
dialysis, anemia, chronic obstructive pulmonary disease, previous percutaneous 
transluminal angioplasty, previous coronary artery bypass graft, congestive heart 
failure, atrial fibrillation. Medication utilization including beta-blocker, diuretic, statin, 
proton-pump inhibitor, or diabetes therapies during the baseline period were assessed 
using outpatient pharmacy claims.1,21 Inpatient medications and over-the-counter 
medications not covered by insurance were not available in this dataset.  
 
Charges and Healthcare Resource Utilization 
All-cause and disease-related charges and healthcare utilization were evaluated for 
patients that escalated antiplatelet therapy by switching from clopidogrel to either 
ticagrelor or prasugrel. All-cause charges were calculated by aggregating total 
outpatient, inpatient, and prescription costs for any encounter or medication. All-cause 
healthcare resource utilization was calculated as a summation of all inpatient or 
outpatient medical encounters occurring on different days or different hospitalizations. 
Cardiovascular-related charges and HRU were similarly calculated but were identified 
with a diagnosis codes for myocardial infarction, stroke, PCI, or other ACS events.22 
Charges for prescription cardiovascular medications included: anticoagulants, 
antiplatelet agents, ACE inhibitors,  angiotensin II receptor blockers, beta blockers, 
calcium channel blockers, cholesterol lowering medications, digitalis preparations, 
diuretics, and vasodilators were aggregated.23 All charges were adjusted to 2019 $US 
equivalents using the annual medical care component of the Consumer Price Index.24 




month (PPPM) amount based on each patient’s follow-up time and accrued expenses or 
encounter frequencies.  
 
Statistical Analysis 
Categorical variables are presented as frequencies (%) and compared using chi-square 
test. Continuous variables are presented as mean ± standard deviation and median 
(quantile 1, quantile 3).  Fisher’s exact tests and/or other non-parametric tests were 
applied as appropriate. Propensity-score matching was used to adjust for confounding 
using a greedy 1:1 matching algorithm. Propensity scores were calculated for each 
patient via a logistic regression model adjusting for baseline comorbidities, aggregated 
baseline charges and medical encounter visits, and several interval factors occurring 
after index hospital discharge and preceding treatment escalation. These interval factors 
included ACS events, revascularization, stroke, days until therapy switch, and 
aggregated interval charges and visit frequencies. Descriptive statistics for the pre-
matched and propensity-matched cohort were summarized for all characteristics 
included within the propensity score model to evaluate balance between treatment 
groups. Charges and healthcare resource utilization were similarly examined. To assess 
the average effect of treatment escalation on outcomes, generalized linear models were 
fitted using a log-link function with gamma distribution or lognormal distribution, 
depending on the outcome of interest, to adjust for the correlation between the PS-
matched groups. Modified park tests and distribution modeling were employed to 




with α=0.05 threshold for significance. All data and statistical processes were performed 




There were 91,682 individuals admitted to the hospital with an acute coronary syndrome 
who underwent percutaneous coronary intervention. Only 71,287 (77%) had 6-months 
of insurance eligibility prior to index hospitalization. After applying the exclusion 
criteria, there were 21,103 (23%) initiated on clopidogrel, 5,040 (6%) initiated on 
prasugrel, and 2,974 (3%) initiated on ticagrelor lowing PCI. Of the clopidogrel 
initiators, 132 switched to ticagrelor and 281 switched to prasugrel (Figure 1). 
 
Unmatched Characteristics and Outcomes 
Prior to propensity-score matching, ticagrelor switchers had higher rates of 
hypertension, hyperlipidemia, chronic kidney disease, and congestive heart failure 
(Table 1). Ticagrelor switchers also had higher rates of ACE/ARB, beta-blocker, statin, 
and diabetic medication use. There was no difference between groups in charges 
associated with all-cause, cardiovascular, and bleeding-related expenditures (Table 2). 
Patients that switched to ticagrelor had similar cardiovascular-related prescription 
expenditures than prasugrel switchers ($360 ±417 vs. $410 ±864 PPPM, t-test p=0.52). 






 Propensity-Score Model 
Variable selected for baseline confounding adjustment were selected in accordance with 
clinical appropriateness and similar studies within this disease category. All variables 
were included in the propensity-score model. Of the 137 patients that switched to 
ticagrelor from clopidogrel and 281 that switched to prasugrel, 123 pairs were selected 
by the 1:1 greedy matching algorithm. Standardized differences after matching were 
below the 10% threshold, indicating that the cohorts were well balanced, except for 
percutaneous coronary intervention, ACE/ARB use, and interval PPPM costs (Table 1). 
There was no statistical difference between the frequency of baseline confounders after 
propensity-score matching. On average, ticagrelor escalators had less days of follow-up 
when compared to the prasugrel group (208 ±116 vs. 240 ±109 days, t-test p=0.03). 
 
Healthcare Charges  
After 1:1 PS-matching, average PPPM costs between groups were largely influenced by 
the highest cost patients as indicated by large standard deviations. The mean PPPM all-
cause cost (ticagrelor vs. prasugrel: $12,137 ±37,016 vs. $18,233 ±71,336 PPPM) was 
largely driven by the cost associated with inpatient hospitalizations ($10,157 ±35,595 
vs. $15,835 ±71,576 PPPM) (Table 2). This relationship remained consistent with mean 
cardiovascular-related total costs ($2,155 ±6,313 vs. $4,340 ±22,627 PPPM) being 
largely influenced by the cardiovascular inpatient costs ($1,647 ±6,321 vs. $3,720 
±22,633 PPPM). All-cause outpatient costs were lower among patients that escalated 




[Quantile 1; Quantile3]: $114 [0; 860] vs. $312 [0; 1,343], p=0.03). There were no 
significant differences in distributions between groups of other cost outcomes (Table 3). 
 
Healthcare Resource Utilization 
The mean PPPM HRU was similar among those who switched from clopidogrel to 
ticagrelor or to prasugrel for all-cause HRU (4.5 ±9.3 vs. 5.5 ±7.4 PPPM), outpatient 
(2.09 ±5.21 vs. 2.3 ±4.55 PPPM) and inpatient (2.45 ±6.90 vs. 2.23 ±6.91 PPPM) 
encounters (Table 2). Ticagrelor escalators had significantly lower PPPM all-cause 
outpatient HRU when compared to prasugrel escalators (0.6 [0; 3.1] vs. 1.0 [0; 2.9] 
PPPM, Wilcoxon sign-rank test p=0.03) (Table 3). However, there was no difference in 
all-cause total healthcare encounters [2.6 [1.1; 4.4] vs. 2.9 [1.5; 6.4] PPPM, p=0.08) or 
all-cause inpatient hospitalizations (0 [0; 3.1] vs. 0 [0; 2.9], p=0.91).  
 
Measures of Treatment Effect from Generalized Linear Models 
Generalized linear models were implemented to evaluate the rate ratio (RR) and 95% 
confidence interval (95%CI) among each outcome within the matched pairs (Table 4). 
The cost outcomes were modeled with a gamma distribution and the HRU outcomes 
were modeled using a lognormal distribution to appropriately accommodate the 
skewness of the observed datapoints. Patients who escalated to ticagrelor experienced 
33% lower all-cause costs (RR: 0.67, 95%CI: 0.44-0.99, p=0.05) when compared to 
those switching to prasugrel. There was no significant difference found in all-cause 
outpatient (RR: 0.94, 95%CI: 0.60-1.48, p=0.80), hospitalizations (RR: 0.58, 95%CI: 




ticagrelor escalators also experienced 49% lower CV-related total costs (RR: 0.51, 
95%CI: 0.33-0.76, p<0.01) driven by the 61% lower CV inpatient costs (RR: 0.39, 
95%CI: 0.16-0.96, p=0.04). There was no difference in outpatient costs between groups 
(RR: 1.55, 95%CI: 0.72-3.3,3 p=0.27). 
 
There was no difference found between groups for all-cause HRU (RR:0.82, 95%CI: 
0.54-1.25, p=0.36), outpatient encounters (RR: 0.76, 95%CI: 0.41-1.42, p=0.39), or 
inpatient hospitalizations (RR: 0.91, 95%CI: 0.52-1.59, p=0.74). Similarly, there was 
no difference found in CV-related HRU (RR:0.77, 95%CI: 0.65-1.07, p=0.45), CV 
outpatient encounters (RR: 1.27, 95%CI: 0.49-3.32, p=0.62), or CV hospitalizations 
(RR: 0.55, 95%CI: 0.19-1.61, p=0.27). 
 
DISCUSSION 
This study found that there were favorable differences in total all-cause costs, total 
cardiovascular-related costs, and cardiovascular-related hospitalization costs among 
patients escalating antiplatelet therapy from clopidogrel to ticagrelor. While direct 
comparisons of the PPPM costs and HRU among propensity matched pairs derived non-
significant findings, we postulate that the combination of small sample size and extreme 
values were the primary factors deriving this result as average values were consistently 
lower among ticagrelor switchers. The wide range in values were driven by extended 
inpatient hospitalizations where patients accrued many thousands of dollars of 
expenditures per day. Even though the data points for these costs are distributional 




costly patients had extended hospitalizations related to myocardial infarction with 
secondary diagnosis codes for respiratory arrest, congestive heart failure, palliative care, 
end stage renal disease, and post-operative infections and were disproportionally 
attributed to prasugrel over ticagrelor escalators.  
 
While we found that escalating to ticagrelor did not influence HRU, it was associated 
with lower all-cause medical costs and cardiovascular hospitalization costs. These 
findings indicate that patients who escalate to ticagrelor experienced less complicated 
and costly cardiovascular hospitalizations that those that switched to prasugrel. As such, 
escalating to ticagrelor should be considered, especially, if health system cost is the 
primary consideration.  
 
To our knowledge there are no other studies investigating costs and healthcare resource 
utilization in patients escalating dual antiplatelet therapy from clopidogrel to either 
ticagrelor or prasugrel. It is difficult to compare the results from this study to others as 
the patients that escalate treatment are, likely, those who fail or are intolerant to 
clopidogrel. It is plausible that the similarities in mechanism of action of clopidogrel 
and prasugrel could contribute to lower costs in the ticagrelor escalators if clopidogrel-
resistant patients experience some level of residual resistance to prasugrel and 
subsequently more costly outcomes. There have been many pharmacodynamic studies 
concluding that the degree of P2Y12 receptor inhibition is similar when comparing 




the translation of acceptable platelet reactivity to longitudinal cost and healthcare 
resource utilization has not been evaluated.  
 
LIMITATIONS 
Our study was subjected to limitations that could implicate some level of residual 
confounding. After the inclusion and exclusion criteria were applied to the data, a small 
population of patients that escalated to either ticagrelor or prasugrel remained. After 1:1 
matching only 123 patient-pairs were included in the analyses. This sample size, 
coupled with extreme outcome values attributed to high-cost and healthcare ultra-
utilizers, made it difficult to identify statistically significant differences of lower 
magnitudes – even though several hundreds of dollars difference may be meaningful. 
Additionally, over-the-counter medications were not captured within this dataset. 
Aspirin, an over-the-counter medication, is a fundamental aspect of dual-antiplatelet 
therapy and its utilization could not be evaluated. As such, we assumed that aspirin 
utilization was not different between groups. Third, this study utilized insurance claims 
data and was exposed to the limitations associated with retrospective studies of this type. 
Additional limitations regarding this data set include generalizability to low income or 
age 65+ individuals as only a portion of these patients are included within this database. 
Fourth, the 1:1 PS-greedy matching approach created comparable comparator groups. 
However, we excluded 14 (10%) unmatched patients who switched to ticagrelor. This 







We found that patients escalating antiplatelet therapy from clopidogrel to ticagrelor 
were associated with less total all-cause costs and total cardiovascular-related costs 
driven by lower cardiovascular-related hospitalization costs when compared to patients 
escalating to prasugrel. Future research with larger sample size is needed to fully 
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N = 21,103 (23%) 
Initiated on ticagrelor 
N = 2,974 (3%) 
Initiated clopidogrel prior to 
March 2012 
N = 15,121 (16%) 
Initiated on prasugrel 




N = 91,682 
6-Month baseline 
insurance eligibility 
N = 71,043 (77%) 
Antiplatelet initiators 
N = 44,238 (48%) 
Prior antiplatelet dispensing  
N = 9,264 (10%) 
( 
No antiplatelet dispensing within 
14-daysdays of discharge 
N = 17,541 (19%) 
Study Population 
N = 29,117 (32%) 
Switched to ticagrelor 
N = 137  
Switched to prasugrel 





Table 1. Baseline and interval comorbidities for unmatched and 1:1 PS-matched cohorts with standardized differences (Std-
diff) 
 Unmatched Cohort   1:1 Matched Cohort    
  Ticagrelor Prasugrel   Ticagrelor Prasugrel    
Std-diff Characteristics n =  137 n = 281 p*  n = 123 n = 123 p*   
Baseline                      
Age (Mean ±SD) 63.7 ±12.5 61.9 ±11 0.15  63.3 ±12.4 
62.
4 ±11.1 0.23   0.08 
Female 43 (31) 98 (35) 0.48  42 (34) 40 (33) 0.79   0.03 
Insurance Type                    
Commercial 72 (53) 171 (61) 
0.12 




Medicare 63 (46) 108 (38)   52 (42) 47 (38)   
Tobacco 26 (19) 81 (29) 0.03   25 (20) 20 (16) 0.41   0.02 
Hypertension 112 (82) 218 (78) 0.33   98 (80) 104 (85) 0.32   0.10 
Hyperlipidemia 113 (82) 213 (76) 0.12   101 (82) 101 (82) 0.99   0.02 
Carotid Artery Stenosis 9 (7) 19 (7) 0.94   6 (5) 7 (6) 0.78   0.03 
Chronic Kidney Disease 16 (12) 16 (6) 0.03   10 (8) 12 (10) 0.66   0.03 
Anemia 17 (12) 25 (9) 0.26   12 (10) 12 (10) 0.99   <0.01 
Chronic Obstructive 
Pulmonary Disease 20 (15) 52 (19) 0.32   18 (15) 17 (14) 0.86   0.02 
Asthma 11 (8) 17 (6) 0.45   10 (8) 7 (6) 0.45   0.06 
Percutaneous Coronary 
Intervention 49 (36) 65 (23) 
<0.0
1   39 (32) 31 (25) 0.26   0.14 
Percutaneous Coronary 
Angioplasty 15 (11) 27 (10) 0.67   11 (9) 15 (12) 0.41   <0.01 
Coronary Artery Bypass 11 (8) 19 (7) 0.64   9 (7) 9 (7) 0.99   <0.01 
Congestive Heart Failure 38 (28) 56 (20) 0.07   28 (23) 33 (27) 0.46   0.04 
Atrial Fibrillation 18 (13) 32 (11) 0.61   14 (11) 20 (16) 0.27   <0.01 





ACE/ARB 61 (45) 101 (36) 0.09   53 (43) 54 (44) 0.90   0.11 
Beta-Blocker 51 (37) 77 (27) 0.04   42 (34) 44 (36) 0.79   0.03 
Diuretic 27 (20) 73 (26) 0.56   18 (15) 24 (20) 0.31   0.04 
Statin 68 (50) 99 (35) 
<0.0
1   58 (47) 58 (47) 0.99   <0.01 
Diabetes 43 (31) 65 (23) 0.07   35 (28) 33 (27) 0.78   0.05 
Proton-Pump Inhibitor 35 (26) 64 (23) 0.53   30 (24) 29 (24) 0.88   0.04 
Anticoagulant 5 (4) 10 (4) 0.95   5 (4) 4 (3) 0.73   0.04 
Clopidogrel 19 (14) 20 (7) 0.02   13 (11) 12 (10) 0.83   0.03 
Strong CYP P-450 
Inducers/Inhibitors 14 (10) 29 (10) 0.99   13 (11) 17 (14) 0.44   0.10 















1 0.79   0.03 
Baseline PPPM HRU 
(Mean ±SD) 3.9 ±6.73 2.5 ±2.93 
<0.0
1   2.9 ±3.2 2.9 ±3.5 0.94   0.01 
Pre-Switch (Interval)                    
Myocardial Infarction 10 (7) 14 (5) 0.33   7 (6) 6 (5) 0.78   0.04 
Stroke 0 (0) 0 (0) -   0 (0) 0 (0) -   - 
Percutaneous Coronary 
Intervention 27 (20) 24 (9) 
<0.0
1   19 (15) 17 (14) 0.72   0.05 
Days until Switch       
         
     
Early: 1-30 days 42 (31) 118 (42) 
0.03 




Late: 30-365 days 93 (68) 161 (57)   89 (72) 72 (59)   
Interval PPPM Costs 
















2 0.41   
0.11 
Interval PPPM HRU 
(Mean ±SD) 4.4 ±6.9 4.8 ±4.2 0.46   4.3 ±5.8 4.6 ±4.9 0.74   
0.04 







Table 2. Average per-patient per-month charges and healthcare resource utilization for unmatched and propensity-score 
matched patients during follow-up period 
 
 Unmatched Cohort  1:1 Matched Cohort 
Outcomes Ticagrelor Prasugrel  Ticagrelor Prasugrel 
(PPPM Mean ±SD) n = 137 n = 281  n = 123 n = 123 
All-Cause          
Total Cost ($) 26,124 ±99,995 13,281 ±5,541  12,137 ±37,016 18,233 ±71,336 
Outpatient Cost ($) 1,474 ±5,070 2,445 ±6,633  1,618 ±5,291 1,937 ±4,261 
Inpatient Cost ($) 24,290 ±99,748 10,425 ±55,564  10,157 ±35,595 15,835 ±71,576 
Rx Cost ($) 360 ±418 411 ±867  362 ±422 460 ±1,193 
Number of Encounters 6.7 ±13.7 5.7 ±11.7  4.5 ±9.3 5.5 ±7.4 
Outpatient Encounter 1.9 ±5.0 2.9 ±8.3  2.1 ±5.2 2.3 ±4.6 
Hospitalizations 4.8 ±12.8 2.8 ±8.5  2.5 ±6.9 3.2 ±7.0 
Cardiovascular          
Total Cost ($) 3,473 ±13,779 2,639 ±15,441  2,155 ±6,313 4,340 ±22,627 
Outpatient Cost ($) 136 ±744 308 ±1,596  146 ±769 184 ±667 
Inpatient Cost ($) 2,976 ±13,827 1,920 ±15,382  1,647 ±6,321 3,720 ±22,633 
Rx Cost ($) 360 ±417 410 ±864  363 ±420 435 ±1,150 
Number of Encounters 0.5 ±1.3 0.4 ±1.1  0.4 ±1.0 0.5 ±1.2 
Outpatient Encounter 0.2 ±0.8 0.2 ±0.7  0.2 ±0.8 0.1 ±0.3 












Table 3. Distributional characteristics of per-patient per-month charges and healthcare resource utilization for unmatched 
and propensity-score matched patients during follow-up period 
  
 Unmatched Cohort  
 Ticagrelor Prasugrel  
Outcomes    n =  137 n = 281 p* 
All-Cause  Median Quantile 1 Quantile 3 Median Quantile 1 Quantile 3  
Total Cost ($) 2,044 765 10,469 2,090 942 7,124 0.62 
Outpatient Cost ($) 26 0 670 510 0 1,820 0.01 
Inpatient Cost ($) 0 0 8,591 0 0 1,745 0.11 
Rx Cost ($) 270 13 515 251 94 462 0.21 
Number of Encounters 2.9 1.1 5.6 2.9 1.4 5.6 0.05 
Outpatient Encounter  0.3 0.0 1.9 1.4 0.0 3.4 0.19 
Hospitalizations  0.0 0.0 3.4 0.0 0.0 1.9 0.02 
Cardiovascular          
Total Cost ($) 456 213 1,025 403 205 851 0.14 
Outpatient Cost ($) 0 0 0 0 0 33 <0.01 
Inpatient Cost ($) 0 0 33 0 0 0 0.01 
Rx Cost ($) 270 73 515 255 98 458 0.42 
Number of Encounters 0.0 0.0 0.4 0.0 0.8 0.3 0.19 
Outpatient Encounter  0.0 0.0 0.0 0.0 0.0 0.1 <0.01 









Table 3. Continued 
 1:1 Matched Cohort  
 Ticagrelor Prasugrel  
Outcomes    n = 123 n = 123 p* 
All-Cause  Median Quantile 1 Quantile 3 Median Quantile 1 Quantile 3   
Total Cost ($) 1,795 699 8,145 2,132 876 8,865 0.75 
Outpatient Cost ($) 114 0 860 312 0 1,343 0.03 
Inpatient Cost ($) 0 0 3,324 0 0 3,508 0.21 
Rx Cost ($) 265 105 458 272 81 426 0.40 
Number of Encounters 2.6 1.1 4.4 2.9 1.5 6.4 0.08 
Outpatient Encounter  0.6 0.0 2.1 1.0 0.0 2.9 0.03 
Hospitalizations  0.0 0.0 3.1 0.0 0.0 2.9 0.91 
Cardiovascular          
Total Cost ($) 408 181 949 433 196 865 0.86 
Outpatient Cost ($) 0 0 0 0 0 23 0.32 
Inpatient Cost ($) 0 0 7 0 0 0 0.74 
Rx Cost ($) 271 80 429 246 72 460 0.84 
Number of Encounters 0.0 0.0 0.3 0.1 0.0 0.5 0.18 
Outpatient Encounter  0.0 0.0 0.0 0.0 0.0 0.1 0.40 
Hospitalizations  0.0 0.0 0.0 0.0 0.0 0.0 0.32 
*The p-values presented were calculated using Mann-Whitney U-test for unmatched and Wilcoxon signed-rank test 


































     
Total Cost ($) 0.67 0.44 0.99 0.05 Gamma 
Outpatient Cost ($) 0.94 0.60 1.48 0.80 Gamma 
Inpatient Cost ($) 0.58 0.31 1.07 0.08 Gamma 
Rx Cost ($) 0.82 0.64 1.05 0.12 Gamma 
Number of Encounters 0.82 0.54 1.25 0.36 LogNormal 
Outpatient Encounter  0.76 0.41 1.42 0.39 LogNormal 
Hospitalizations  0.91 0.52 1.59 0.74 LogNormal 
  
     
Cardiovascular 
     
Total Cost ($) 0.51 0.33 0.76 <0.01 Gamma 
Outpatient Cost ($) 1.55 0.72 3.33 0.27 Gamma 
Inpatient Cost ($) 0.39 0.16 0.96 0.04 Gamma 
Rx Cost ($) 0.83 0.65 1.07 0.15 Gamma 
Number of Encounters 0.77 0.39 1.52 0.45 LogNormal 
Outpatient Encounter  1.27 0.49 3.32 0.62 LogNormal 
Hospitalizations  0.55 0.19 1.61 0.27 LogNormal 




Table 5. Distributional statistics for all-cause outcomes 
  Unmatched 1:1 PS-Matched 
PPPM Total Cost Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max ($) 1,033,226 635,608   294,777 635,607 
 
Q3 ($) 10,469 7,124   8,145 8,865 
 
Median ($) 2,044 2,090 0.92
* 
1,795 2,132 0.37* 
Q1 ($) 765 942   699 876 
 





   






99,995 5,541   37,016 71,336 
 
 
        
  Unmatched 1:1 PS-Matched 
PPPM Outpatient 
Costs 
Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max ($) 45,811 81,469   45,810 25,465 
 
Q3 ($) 670 1,820   860 1,343 
 
Median ($) 26 510 <0.0
1 
114 312 0.06* 
Q1 ($) 0 0   0 0 
 





   






5,070 6,633   5,291 4,261 
 
 
        
  Unmatched 1:1 PS-Matched 
PPPM Inpatient 
Cost 
Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max ($) 1,033,226 635,146   294,634 635,145 
 
Q3 ($) 8,591 1,745   3,324 3,508 
 
Median ($) 0 0 <0.0
1 
0 0 0.51* 
Q1 ($) 0 0   0 0 
 















99,748 55,564   35,595 71,576 
 
 
        
  Unmatched 1:1 PS-Matched 
PPPM 
Prescription Cost 
Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max ($) 2,365 12,585   12,585 2,365 
 
Q3 ($) 515 462   458 426 
 
Median ($) 270 251 0.60
* 
265 272 0.70* 
Q1 ($) 73 94   105 81 
 





   











Unmatched 1:1 PS-Matched 
PPPM No. of 
Encounters 
Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max 98.2 137   83.7 43.7 
 
Q3 5.58 5.57   4.42 6.35 
 
Median 2.90 2.88 0.92* 2.57 2.88 0.52* 
Q1 1.09 1.43   1.06 1.45 
 





   
Mean 6.66 5.67 0.03** 4.54 5.53 0.35** 
Standard Deviation 13.74 11.67   9.25 7.43 
 
 
        




Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max 49.0 126   49.0 43.4 
 





Median 0.25 1.37 <0.01 0.62 1.01 0.16* 
Q1 0.00 0.00   0.00 0.00 
 





   
Mean 1.91 2.90 0.21** 2.09 2.30 0.37** 
Standard Deviation 5.01 8.35   5.21 4.55 
 
 
        
  Unmatched 1:1 PS-Matched 
PPPM No. 
Hospitalizations 
Ticagrelor Prasugrel p Ticagrelor Prasugrel p 
N 135 279   123 123 
 
Max 98.2 95.5   63.5 38.3 
 
Q3 3.40 1.90   3.07 2.88 
 
Median 0.00 0.00 <0.01 0.00 0.00 0.60* 
Q1 0.00 0.00   0.00 0.00 
 





   
Mean 4.75 2.77 0.06** 2.45 3.23 0.74** 
Standard Deviation 12.76 8.51   6.90 6.97 
 
*The p-value presented was calculated to compare distributions Mann-Whiney U for 
unmatched and Wilcoxon singed-rank test for matched pairs 
**The p-value presented was calculated to compare the distributional mean using a t-test 





Table 6. Distributional statistics for cardiovascular outcomes 
 
  Unmatched 1:1 PS-Matched 
PPPM Total CV Cost Ticagrelor Prasugrel p Ticagrelor Prasugr
el 
p 
N 137 281   128 128 
 
Max ($) 144,736 226,693   43,685 226,69
3 
 
Q3 ($) 1,025 851   949 865 
 
Median ($) 456 403 0.6
0* 
408 433 0.80* 
Q1 ($) 213 205   181 196 
 





   
Mean ($) 3,473 2,639 0.1
3*
* 
2,155 4,340 0.29** 





      
  Unmatched 1:1 PS-Matched 
PPPM Outpatient CV 
Costs 
Ticagrelor Prasugrel p Ticagrelor Prasugr
el 
p 
N 137 281   128 128 
 
Max ($) 7,380 20,138   7,380 4,986 
 
Q3 ($) 0 33   0 23 
 
Median ($) 0 0 <0.
01
* 
0 0 <0.01* 
Q1 ($) 0 0   0 0 
 





   
Mean ($) 136 308 0.2
3*
* 
146 184 0.67** 
Standard Deviation ($) 744 1,596   769 667 
 
 
        
  Unmatched 1:1 PS-Matched 
PPPM Inpatient CV 
Cost 
Ticagrelor Prasugrel p Ticagrelor Prasugr
el 
p 
N 137 281   128 128 
 
Max ($) 144,736 226,231   43,402 226,23
1 
 





Median ($) 0 0 0.0
3* 
0 0 0.56* 
Q1 ($) 0 0   0 0 
 





   
Mean ($) 2,976 1,920 0.1
6*
* 
1,647 3,720 0.31** 





      
  Unmatched 1:1 PS-Matched 
PPPM CV 
Prescription Cost 
Ticagrelor Prasugrel p Ticagrelor Prasugr
el 
p 
N 137 281   128 128 
 
Max ($) 2,365 12,585   2,365 12,585 
 
Q3 ($) 515 458   429 460 
 
Median ($) 270 255 0.7
5* 
271 246 0.45* 
Q1 ($) 73 98   80 72 
 





   
Mean ($) 360 410 0.5
2*
* 
363 435 0.50** 





  Unmatched 1:1 PS-Matched 




Prasugrel p Ticagrelor Prasugrel p 
N 137 281   128 128 
 
Max 10.00 10.89   8.14 10.89 
 
Q3 0.35 0.34   0.34 0.51 
 
Median 0.00 0.08 0.10* 0.00 0.10 0.02* 
Q1 0.00 0.00   0.00 0.00 
 





   
Mean 0.47 0.38 0.45** 0.36 0.47 0.44** 
Standard 
Deviation 














Prasugrel p Ticagrelor Prasugrel p 
N 137 281   128 128 
 
Max 8.14 10.00   8.14 2.11 
 
Q3 0.00 0.13   0.00 0.13 
 




Q1 0.00 0.00   0.00 0.00 
 





   
Mean 0.17 0.17 0.96** 0.18 0.14 0.61** 
Standard 
Deviation 
0.79 0.66   0.81 0.34 
 
 
        






Prasugrel p Ticagrelor Prasugrel p 
N 137 281   128 128 
 
Max 10.00 10.89   6.74 10.89 
 
Q3 0.09 0.00   0.00 0.00 
 
Median 0.00 0.00 0.08* 0.00 0.00 0.88* 
Q1 0.00 0.00   0.00 0.00 
 





   
Mean 0.30 0.22 0.38** 0.18 0.32 0.23** 
Standard 
Deviation 
1.12 0.88   0.68 1.20 
 
*The p-value presented was calculated to compare distributions Mann-Whiney U 
for unmatched and Wilcoxon singed-rank test for matched pairs 
**The p-value presented was calculated to compare the distributional mean using a 








A.1-A.5 SUPPLIMENTAL FIGURES FOR MANUSCRIPT 1: 
 
Appendix Figure A.1: Intention-to-treat (ITT) estimated probability of event-free 
survival for death, myocardial infarction, or stroke in clopidogrel versus ticagrelor 













































Appendix Figure A.2: As-treated (AT) estimated probability of event-free survival for 
death, myocardial infarction, or stroke in clopidogrel versus ticagrelor following an 
















































Appendix Figure A.3: Intention-to-treat with censor-weighting (ITT-CW) estimated 
probability of event-free survival for death, myocardial infarction, or stroke in 














































Appendix Figure A.4: Time-dependent exposure (TD) estimated probability of event-
free survival for death, myocardial infarction, or stroke in clopidogrel versus ticagrelor 

















































Appendix Figure A.5: Time-dependent with censor-weighting (TD-CW) estimated 
probability of event-free survival for death, myocardial infarction, or stroke in 














































Appendix Table B.1: Administrative claims codes for various comorbidities  
 
 
Variable Code Code Type 
Acute coronary syndromes "410" "411" ICD-9 Dx 
Percutaneous coronary 
intervention 
 "3601" "3602" "3605" 
"3606" "3607" "3609" 
"0066" "92980" "92981" 
"92982" "92984" 
CPT & IDC-9 
Proc 
Fibrinolysis 37201 "37211" "37212" 
"37213" "37214" "37195" 
"92977" "9910" 
CPT & IDC-9 
Proc 
Tobacco "3051" "V1582" ICD-9 Dx 
Hypertension "4011" "4019" "4010" 
"40200" "40201" "40210" 
"40211" "40290" "40291" 
"4030" "40300" "40301" 
"4031" "40310" "40311" 
"4039" "40390" "40391" 
"4040" "40400" "40401" 
"40402" "40403" "4041" 
"40410" "40411" "40412" 
"40413" "4049" "40490" 
"40491" "40492" "40493" 
"40501" "40509" "40511" 
"40519" "40591" "40599" 
"4372" 
ICD-9 Dx 






Diabetes mellitus "24900" "25000" "25001" 
"7902" "79021" "79022" 
"79029" "7915" "7916" 
"V4585" "V5391" "V6546" 
"24901" "24910" "24911" 
"24920" "24921" "24930" 
"24931" "24940" "24941" 
"24950" "24951" "24960" 
"24961" "24970" "24971" 
"24980" "24981" "24990" 
"24991" "25002" "25003" 
"25010" "25011" "25012"  
"25013" "25020" "25021" 
"25022" "25023" "25030" 
"25031" "25032" "25033" 
"25040" "25041" "25042" 
"25043" "25050" "25051" 
"25052" "25053" "25060"  
"25061" "25062" "25063" 
"25070" "25071" "25072" 
"25073" "25080" "25081"  
"25082" "25083" "25090" 
"25091" "25092" "25093" 
ICD-9 Dx 
Coronary artery stenosis "43310" "43311" ICD-9 Dx 
Peripheral vascular disease "4400" "4401" "4402" 
"44020" "44021" "44022" 
"44023" "44029" "4404" 
"4408" "4409" "4439" 
"5570" "5571" "5579" 
ICD-9 Dx 
Dialysis "5856" ICD-9 Dx 
Chronic Kidney Disease "585" "5851" "5852" "5853" 
"5854" "5855" "5859" 
ICD-9 Dx 
Anemia "2800" "2801" "2808" 
"2809" "2810" "2811" 
"2812" "2813" "2814" 
"2818" "2819" "2820" 
"2821" "2822" "2823" 
"2824" "28240" "28243" 
"28244" "28245" "28246" 
"28247" "28249" "2827" 
"2828" "2829" "2830" 
"2831" "28310" "28311" 
"28319" "2832" "2839" 
"2840" "28401" "28409" 
"2841" "28411" "28412" 





"28481" "28489" "2849" 
"2850" "28521" "28522" 
"28529" "2858" "2859" 
Chronic obstructive pulmonary 
disorder 
"490" "4910" "4911" "4912" 
"49120" "49121" "49122" 
"4918" "4919" "4920" 
"4928" "494" "4940" "4941" 
"496" 
ICD-9 Dx 
Asthma "49300" "49301" "49302" 
"49310" "49311" "49312" 
"49320" "49321" "49322" 
"49381" "49382" "49390" 
"49391" "49392") 
ICD-9 Dx 
Congestive heart failure "428" "4280" "4281" "4282" 
"42820" "42821" "42822" 
"42823" "4283" "42830" 
"42831" "42832" "42833" 
"4284" "42840" "42841" 
"42842" "42843" "4289" 
ICD-9 Dx 






Appendix Table B.2:  Coding algorithms for outcomes 
 
ICD-9 Coding Algorithm Exclusion PPV Source 
Myocardial 
infarction58 
3 <= LOS <= 
180 
   
 
410.xx 410.x2 0.94 Kiyota et al.      
Ischemic 
stroke 
3 <= LOS <= 
180 




0.955 Wahl et al.  
434.x1 
   
     
     
     
Death 




   




   
 
430 (SAH) 800-804 0.86 Tirschwell et 
al.  
431 (ICH) 850-854 0.90 Tirschwell et 










0.878 Wahl et al.  
531.2X 
   
 
531.4X 
   
 
531.6X 
   
 
532.0X 
   
 
532.2X 
   
 
532.4X 
   
 
532.6X 
   
 
533.0X 
   
 
533.2X 
   
 
533.4X 
   
 
533.6X 
   
 
534.0X 
   
 
534.2X 
   
 
534.4X 
   
 
534.6X 










   
 
43255 (CPT) 







Appendix Table C.1 Generic name roots for cardiovascular medications queried in 




   
BENAZEPRIL FONDAPARINUX NADOLOL TRIAMTERENE 
CAPTOPRIL HEPARIN NEBIVOLOL EPLERENONE 
ENALAPRIL WARFARIN PINDOLOL SPIRONOLACTON
E 
LISINOPRIL ASPIRIN PROPANOLOL AMILORIDE 
QUINAPRIL CILOSTAZOL SOTALOL TORSEMIDE 
RAMIPRIL CLOPIDOGREL TIMOLOL TRIAMTERENE 
CANDESARTAN DIPYRAMIDAMOLE AMLODIPINE ATORVASTATIN 
EPROSARTAN PRASUGREL BEPRIDIL FLUVASTATIN 
IRBESARTAN TICLOPIDINE DILTIAZEM LOVASTATIN 
LOSARTAN CLONIDINE FELODIPINE PRAVASTATIN 
TELMISARTAN DOXAZOSIN ISRADIPINE ROSUVASTATIN 
VALSARTAN HYDRALAZINE NICARDIPINE SIMVASTATIN 
AMIODARONE METHYLDOPA NIFEDIPINE FENOFIBRATE 
DISOPYRAMID
E 




FLECAINIDE PHENTOLAMINE DIGOXIN CHOLESTYRAMI
NE 
MEXILETINE PRAZOSIN AMILORIDE COLESTIPOL 
PROCAINAMID
E 
TERAZOSIN BUMETANIDE NIACIN 
PROPAFENONE ACEBUTOLOL CHLOROTHIAZIDE NITROGLYCERIN 
QUINADINE BETAXOLOL ETHACRYNIC RANOLAZINE 




DALTEPARIN LABETALOL INDAPAMIDE 
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